Publication | Closed Access

French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC)

Unresectable Pharyngeal CarcinomaRadiation TherapyMedicineCisplatin/5-fluorouracil ChemotherapyMolecular OncologyCancer TreatmentOncologyRadiation OncologyConcurrent Twice-a-day RadiotherapyCancer ResearchRadiologyHealth Sciences